These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 1354681)

  • 21. N-terminal residues 105-117 of HIV-1 gp120 are not involved in CD4 binding.
    el Ahmar W; Poumbourios P; McPhee DA; Kemp BE
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):855-8. PubMed ID: 1720631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthetic peptides allow discrimination of structural features of CD4(81-92) important for HIV-1 infection versus HIV-1-induced syncytium formation.
    Lifson JD; Rausch DM; Kalyanaraman VS; Hwang KM; Eiden LE
    AIDS Res Hum Retroviruses; 1991 Jun; 7(6):521-7. PubMed ID: 1931230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD4 molecules with a diversity of mutations encompassing the CDR3 region efficiently support human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion.
    Broder CC; Berger EA
    J Virol; 1993 Feb; 67(2):913-26. PubMed ID: 8419649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple effects of CD4 CDR3-related peptide derivatives showing anti-HIV-1 activity on HIV-1 gp120 functions.
    Ohki K; Kimura T; Jones IM; Morita F; Ikuta K
    Vaccine; 1994 Mar; 12(4):343-50. PubMed ID: 8178557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short synthetic peptides derived from viral proteins compete with HIV gp120 for the binding to CD4 receptors.
    Chersi A; Pugliese O; Federico A; Viora M
    Viral Immunol; 2000; 13(4):547-54. PubMed ID: 11192301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Binding to CD4 of synthetic peptides patterned on the principal neutralizing domain of the HIV-1 envelope protein.
    Autiero M; Abrescia P; Dettin M; Di Bello C; Guardiola J
    Virology; 1991 Dec; 185(2):820-8. PubMed ID: 1720590
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV interactions with CD4: a continuum of conformations and consequences.
    Eiden LE; Lifson JD
    Immunol Today; 1992 Jun; 13(6):201-6. PubMed ID: 1627247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal antibodies to a CD4 peptide derivative which includes the region corresponding to an immunoglobulin CDR3: evidence of the involvement of pre-CDR3-related region in HIV-1 and host cell interaction.
    Ohki K; Kimura T; Ohmura K; Morikawa Y; Jones IM; Azuma I; Ikuta K
    Mol Immunol; 1992 Nov; 29(11):1391-400. PubMed ID: 1406723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Ixodes scapularis salivary protein, salp15, prevents the association of HIV-1 gp120 and CD4.
    Juncadella IJ; Garg R; Bates TC; Olivera ER; Anguita J
    Biochem Biophys Res Commun; 2008 Feb; 367(1):41-6. PubMed ID: 18162176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV type 1 V3 peptide constructs act differently on HIV type 1 infection of peripheral blood lymphocytes and macrophages.
    Benjouad A; Seddiki N; Ylisastigui L; Gluckman JC
    AIDS Res Hum Retroviruses; 1997 Feb; 13(3):219-26. PubMed ID: 9115808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD4-derived synthetic peptide blocks the binding of HIV-1 GP120 to CD4-bearing cells and prevents HIV-1 infection.
    Shapira-Nahor O; Golding H; Vujcic LK; Resto-Ruiz S; Fields RL; Robey FA
    Cell Immunol; 1990 Jun; 128(1):101-17. PubMed ID: 1971526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A functional, discontinuous HIV-1 gp120 C3/C4 domain-derived, branched, synthetic peptide that binds to CD4 and inhibits MIP-1alpha chemokine binding.
    Howie SE; Fernandes ML; Heslop I; Hewson TJ; Cotton GJ; Moore MJ; Innes D; Ramage R; Harrison DJ
    FASEB J; 1999 Mar; 13(3):503-11. PubMed ID: 10064617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of CD4-gp120 activation intermediates during human immunodeficiency virus type 1 syncytium formation.
    Hart TK; Truneh A; Bugelski PJ
    AIDS Res Hum Retroviruses; 1996 Sep; 12(14):1305-13. PubMed ID: 8891109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peptides derived from the CDR3-homologous domain of the CD4 molecule are specific inhibitors of HIV-1 and SIV infection, virus-induced cell fusion, and postinfection viral transmission in vitro. Implications for the design of small peptide anti-HIV therapeutic agents.
    Rausch DM; Hwang KM; Padgett M; Voltz AH; Rivas A; Engleman E; Gaston I; McGrath M; Fraser B; Kalyanaraman VS
    Ann N Y Acad Sci; 1990; 616():125-48. PubMed ID: 2078014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD4-derived peptide and sulfated polysaccharides have similar mechanisms of anti-HIV activity based on electrostatic interactions with positively charged gp120 fragments.
    Meshcheryakova D; Andreev S; Tarasova S; Sidorova M; Vafina M; Kornilaeva G; Karamov E; Khaitov R
    Mol Immunol; 1993 Aug; 30(11):993-1001. PubMed ID: 8102473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Jacalin, a lectin with anti-HIV-1 properties, and HIV-1 gp120 envelope protein interact with distinct regions of the CD4 molecule.
    Corbeau P; Haran M; Binz H; Devaux C
    Mol Immunol; 1994 Jun; 31(8):569-75. PubMed ID: 8196669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human immunodeficiency virus type 1 (HIV-1) superinfection of a cell clone converting it from production of defective to infectious HIV-1 is mediated predominantly by CD4 regions other than the major binding site for HIV-1 glycoproteins.
    Ohki K; Kishi M; Ohmura K; Morikawa Y; Jones IM; Azuma I; Ikuta K
    J Gen Virol; 1992 Jul; 73 ( Pt 7)():1761-72. PubMed ID: 1629701
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigations using photo affinity labeled analogues confirm the binding between sCD4 and the PND of HIV-1, MN.
    Dettin M; Scarinci C; Seraglia R; Di Bello C
    Biochem Biophys Res Commun; 1997 Dec; 241(2):584-8. PubMed ID: 9425315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Morphometric analysis of recombinant soluble CD4-mediated release of the envelope glycoprotein gp120 from HIV-1.
    Kirsh R; Hart TK; Ellens H; Miller J; Petteway SA; Lambert DM; Leary J; Bugelski PJ
    AIDS Res Hum Retroviruses; 1990 Oct; 6(10):1209-12. PubMed ID: 2252640
    [No Abstract]   [Full Text] [Related]  

  • 40. Further insights on the inhibition of HIV type 1 infection in vitro by CD4-modified synthetic peptides containing phenylalanine.
    Prieto I; Lasarte JJ; Sarobe P; Golvano J; Civeira MP; Gullón A; Prieto J; Borrás-Cuesta F
    AIDS Res Hum Retroviruses; 1996 Jul; 12(11):1023-30. PubMed ID: 8827218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.